Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study.

  • Clinical Trial, Phase II
  • Journal Article
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

The Lancet. Infectious diseases, Volume: 18, Issue: 8
August 13, 2018
Alejandro Llanos-Cuentas A, Martin Casapia M, Raúl Chuquiyauri R, Juan-Carlos Hinojosa JC, Nicola Kerr N, Maria Rosario M, Stephen Toovey S, Robert H Arch RH, Margaret A Phillips MA, Felix D Rozenberg FD, Jade Bath J, Caroline L Ng CL, Annie N Cowell AN, Elizabeth A Winzeler EA, David A Fidock DA, Mark Baker M, Jörg J Möhrle JJ, Rob Hooft van Huijsduijnen R, Nathalie Gobeau N, Nada Araeipour N, Nicole Andenmatten N, Thomas Rückle T, Stephan Duparc S

DSM265 is a novel, long-duration inhibitor of plasmodium dihydroorotate dehydrogenase (DHODH) with excellent selectivity over human DHODH and activity against blood and liver stages of Plasmodium falciparum. This study aimed to assess the efficacy of DSM265 in patients with P falciparum or Plasmodium vivax malaria infection.

Courtesy of the U.S. National Library of Medicine